Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Insight, 2026

DelveInsight's, "Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Insight, 2026" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Ankylosing Spondylitis (Bekhterev's Disease) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Ankylosing Spondylitis (Bekhterev's Disease) : Understanding

Ankylosing Spondylitis (Bekhterev's Disease): Overview

Ankylosing spondylitis (AS), also known as Bekhterev's disease, is a chronic inflammatory rheumatic disease that primarily affects the axial skeleton, particularly the spine and sacroiliac (SI) joints. It is characterized by chronic inflammatory back pain, progressive spinal stiffness, and reduced spinal mobility. Peripheral joints, digits, and entheses may also be affected, while extra-articular manifestations can include acute anterior uveitis, inflammatory bowel disease, and psoriasis.

The exact cause of AS remains unknown, but genetic susceptibility plays an important role. The disease is strongly associated with the human leukocyte antigen HLA-B27, although not all HLA-B27-positive individuals develop AS. Familial predisposition is also observed, with an increased risk among relatives of affected individuals.

The primary pathological process in AS is enthesitis, or inflammation at the sites where tendons and ligaments attach to bone. This inflammatory process involves immune cells, including CD4 and CD8 T lymphocytes and macrophages, along with cytokines such as tumor necrosis factor-alpha (TNF-a) and transforming growth factor-beta (TGF-B). Persistent inflammation promotes fibrosis and abnormal bone formation, eventually resulting in syndesmophyte formation, joint fusion, and the characteristic "bamboo spine" appearance in advanced disease.

Diagnosis is based on clinical assessment, laboratory investigations, and imaging. Typical features include inflammatory back pain beginning before 40 years of age, gradual onset, improvement with exercise but not rest, and nocturnal pain. ESR and CRP may be elevated in active disease, although normal levels do not exclude AS. Pelvic/spinal radiography is commonly used to identify sacroiliitis and structural changes, while MRI can detect earlier inflammatory changes, including bone marrow edema, in the sacroiliac joints and spine. HLA-B27 testing can provide supportive evidence but is not diagnostic on its own.

Treatment aims to reduce pain and stiffness, maintain spinal mobility and physical function, and prevent complications. Regular exercise, physical therapy, postural training, and rehabilitation are important components of management. NSAIDs are generally used as first-line pharmacological therapy. In patients with inadequate response, biologic therapies such as TNF inhibitors may be used. Systemic glucocorticoids are generally not recommended for axial AS, although local steroid injections may be considered for selected manifestations.

"Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ankylosing Spondylitis (Bekhterev's Disease) pipeline landscape is provided which includes the disease overview and Ankylosing Spondylitis (Bekhterev's Disease) treatment guidelines. The assessment part of the report embraces, in depth Ankylosing Spondylitis (Bekhterev's Disease) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ankylosing Spondylitis (Bekhterev's Disease) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

• The companies and academics are working to assess challenges and seek opportunities that could influence Ankylosing Spondylitis (Bekhterev's Disease) R&D. The therapies under development are focused on novel approaches to treat/improve Ankylosing Spondylitis (Bekhterev's Disease) .

Ankylosing Spondylitis (Bekhterev's Disease) Emerging Drugs Chapters

This segment of the Ankylosing Spondylitis (Bekhterev's Disease) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Ankylosing Spondylitis (Bekhterev's Disease) Emerging Drugs

• LNK01001: Lynk Pharmaceuticals /Simcere Pharmaceutical

LNK01001 is an investigational, oral small-molecule Janus kinase 1 (JAK1) inhibitor being developed by Lynk Pharmaceuticals for the treatment of ankylosing spondylitis (AS). The drug is designed to selectively inhibit JAK1 signaling, a pathway involved in the downstream signaling of multiple pro-inflammatory cytokines implicated in the pathogenesis of AS. LNK01001 has demonstrated clinical development potential in inflammatory diseases and is being evaluated for its ability to reduce inflammation and improve disease-related symptoms and functional outcomes in patients with AS. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Ankylosing Spondylitis (Bekhterev's Disease) .

• Vilamakitug: XBiotech, Inc.

Vilamakitug is an novel, fully human monoclonal antibody developed by XBiotech, Inc., engineered to specifically target and neutralize interleukin-1 alpha (IL-1a), a key driver of systemic tissue inflammation. Currently being investigated as a targeted biologic therapy for ankylosing spondylitis (AS), vilamakitug aims to intercept inflammatory signaling early in the immune cascade, offering a promising approach to alleviating chronic spinal pain, reducing morning stiffness, and slowing down joint degeneration in patients with active disease. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Ankylosing Spondylitis (Bekhterev's Disease).

• DB015: DotBio

DB015 is a bispecific antibody asset being developed by DotBio for the treatment of inflammatory and autoimmune conditions, specifically targeting rheumatoid arthritis and ankylosing spondylitis (AS). Built using DotBio's modular human domain antibody platform, DB015 incorporates an IL-17-based bispecific design to inhibit key pro-inflammatory cytokine pathways driving joint inflammation and axial tissue damage. Currently, the drug is being evaluated in the Preclinical stage of its development for the treatment of Ankylosing Spondylitis (Bekhterev's Disease).

Ankylosing Spondylitis (Bekhterev's Disease) : Therapeutic Assessment

This segment of the report provides insights about the different Ankylosing Spondylitis (Bekhterev's Disease) drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Ankylosing Spondylitis (Bekhterev's Disease)

There are approx. 20+ key companies which are developing the therapies Ankylosing Spondylitis (Bekhterev's Disease). The companies which have their Ankylosing Spondylitis (Bekhterev's Disease) drug candidates in the most advanced stage, i.e. Phase III include, Lynk Pharmaceuticals, and others.

• Phases

DelveInsight's report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Ankylosing Spondylitis (Bekhterev's Disease) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Ankylosing Spondylitis (Bekhterev's Disease): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ankylosing Spondylitis (Bekhterev's Disease) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ankylosing Spondylitis (Bekhterev's Disease) drugs.

Ankylosing Spondylitis (Bekhterev's Disease) Report Insights

• Ankylosing Spondylitis (Bekhterev's Disease) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Ankylosing Spondylitis (Bekhterev's Disease) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Ankylosing Spondylitis (Bekhterev's Disease) drugs?
• How many Ankylosing Spondylitis (Bekhterev's Disease) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ankylosing Spondylitis (Bekhterev's Disease) ?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Ankylosing Spondylitis (Bekhterev's Disease) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Ankylosing Spondylitis (Bekhterev's Disease) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Lynk Pharmaceuticals
• Simcere Pharmaceutical
• DotBio
• Fosun Pharma
• Junshi Biosciences
• XBiotech, Inc.
• Qyuns Pharmaceuticals
• Huadong Medicine
• Jiangsu Vcare
• Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
• Shenzhen Huishan Biotechnology Co., Ltd.
• Merck

Key Products

• LNK01001
• DB015
• Roconkibart
• Vilamakitug
• VC005
• Amdokitug(608)
• HS_SW01
• QX002N
• Tulisokibart